Spots Global Cancer Trial Database for neurofibroma
Every month we try and update this database with for neurofibroma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment | NCT05957679 | Spinal Cord Tum... | Magnetic Resona... Assessment and ... | 18 Years - 80 Years | Shengjing Hospital | |
| Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas | NCT00716469 | Neurofibroma | LS11 | 3 Years - 21 Years | Children's Hospital of Philadelphia | |
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1 | NCT05199376 | Neurofibroma Neurofibroma, P... | Cryotherapy | 18 Years - | Centre Leon Berard | |
| Natural History Study of Cutaneous Neurofibromas in People With NF1 | NCT05581511 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Cutaneous Neuro... | Evaluation of t... | 1 Year - 100 Years | Johns Hopkins University | |
| MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment | NCT05957679 | Spinal Cord Tum... | Magnetic Resona... Assessment and ... | 18 Years - 80 Years | Shengjing Hospital | |
| Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma | NCT02988726 | CNS Tumor | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II | NCT02728388 | NEUROFIBROMATOS... | aminolevulinic ... | 14 Years - 30 Years | Medical College of Wisconsin | |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T | NCT02332902 | Neurofibromatos... | Everolimus | 18 Years - | The University of Texas Health Science Center, Houston | |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | NCT00314119 | Neurofibromatos... Neurofibroma | 20 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | NCT03820778 | Neurofibromatos... Neurofibroma Atypical Neurof... Atypical Neurof... Plexiform Neuro... Von Recklinghau... | Whole Body MRI | 8 Years - 30 Years | Children's National Research Institute | |
| Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) | NCT00111384 | Neurofibromatos... Legius Syndrome | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas | NCT00716469 | Neurofibroma | LS11 | 3 Years - 21 Years | Children's Hospital of Philadelphia | |
| Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | NCT05891847 | Neurofibroma | - | AstraZeneca | ||
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
